Potential methods for improving the efficacy of mesenchymal stem cells in the treatment of inflammatory bowel diseases.

摘要: Inflammatory bowel diseases (IBD) are a group of chronic recurrent gastrointestinal inflammatory diseases, including ulcerative colitis (UC), Crohn's disease (CD) and IBD unclassified. The pathogenesis may be related to the mucosal immune dysfunction in genetically susceptible hosts affected by environmental factors. Current therapeutic agents mainly include aminosalicylates, corticosteroids, immunosuppressive drugs novel biological agents. purpose treatment is suppress inflammation prevent irreversible structural damage. However, long-term application these lead multiple adverse effects not always effective. Mesenchymal stem cells (MSCs) multipotent progenitors with low immunogenicity, which can obtained expanded easily. They play an important role regulating responses repairing damaged tissues vivo. Therefore, MSCs considered promising option for IBD. Nonetheless, there many factors that reduce efficacy MSCs, such as gradual deterioration functional age, recruitment persistence vivo different routes administration. In recent years, researchers have been able improve pretreatment, genetic modification or co-application other substances, well using tissue-derived cells, administration methods doses. This article reviews provide references more effective future.